Literature DB >> 10438521

Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism.

J M Louis1, E M Wondrak, A R Kimmel, P T Wingfield, N T Nashed.   

Abstract

Previously it was demonstrated using a model precursor that processing at the N terminus of the HIV-1 protease (PR) precedes processing at its C terminus. We now show the expression, purification, and kinetics of the autoprocessing reaction of a PR precursor linked to 53 amino acids of the native flanking transframe region (DeltaTFP-p6(pol)) of Gag-Pol and containing its two native cleavage sites. The PR contains the two cysteine residues exchanged to alanines, mutations that do not alter the kinetics or the structural stability of the mature PR. DeltaTFP-p6(pol)-PR, which encompasses the known PR inhibitor sequence Glu-Asp-Leu within DeltaTFP, undergoes cleavage at the DeltaTFP/p6(pol) and p6(pol)/PR sites in two consecutive steps to produce the mature PR. Both DeltaTFP-p6(pol)-PR and p6(pol)-PR exhibit low intrinsic enzymatic activity. The appearance of the mature PR is accompanied by a large increase in catalytic activity. It follows first-order kinetics in protein concentration with a rate constant of 0.13 +/- 0.01 min(-1) in 0.1 M acetate at pH 4.8. The pH-rate profile for the observed first-order rate constant is bell-shaped with two ionizable groups of pK(a) 4.9 and 5.1. The rate constant also exhibits approximately 7-fold higher sensitivity to urea denaturation as compared with that of the mature PR, suggesting that the cleavage at the N terminus of the PR domain from the precursor leads to the stabilization of the dimeric structure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438521     DOI: 10.1074/jbc.274.33.23437

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro.

Authors:  S D Parker; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

3.  Rational design of p53, an intrinsically unstructured protein, for the fabrication of novel molecular sensors.

Authors:  Melissa L Geddie; Taryn L O'Loughlin; Kristen K Woods; Ichiro Matsumura
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

4.  Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.

Authors:  Speranta Avram; Cristian Bologa; Maria-Luiza Flonta
Journal:  J Mol Model       Date:  2005-02-16       Impact factor: 1.810

5.  The maturation of HIV-1 protease precursor studied by discrete molecular dynamics.

Authors:  Sachie Kimura; Martina Caldarini; Ricardo A Broglia; Nikolay V Dokholyan; Guido Tiana
Journal:  Proteins       Date:  2013-11-22

6.  Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors.

Authors:  John M Louis; Annie Aniana; Irene T Weber; Jane M Sayer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

7.  Kinetic characterization of the critical step in HIV-1 protease maturation.

Authors:  S Kashif Sadiq; Frank Noé; Gianni De Fabritiis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

8.  The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.

Authors:  John M Louis; Ying Zhang; Jane M Sayer; Yuan-Fang Wang; Robert W Harrison; Irene T Weber
Journal:  Biochemistry       Date:  2011-05-03       Impact factor: 3.162

9.  Cysteine 95 and other residues influence the regulatory effects of Histidine 69 mutations on Human Immunodeficiency Virus Type 1 protease autoprocessing.

Authors:  Liangqun Huang; Alyssa Hall; Chaoping Chen
Journal:  Retrovirology       Date:  2010-03-23       Impact factor: 4.602

10.  Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.

Authors:  Nathalie Dautin; Gouzel Karimova; Daniel Ladant
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.